

Financial highlights

Total Revenue¹

Up 3% at actual rate of exchange to \$45,811 million (up 6% at CER), comprising Product Sales of \$43,789 million (up 2%; 4% at CER), Alliance Revenue of \$1,428 million (up 89%; 89% at CER) and Collaboration Revenue of \$594 million (down 1%; 1% at CER)

2023	\$45,811m
2022	\$44,351m
2021	\$37,417m

\$45.8bn

Net cash flow from operating activities

Up 5% at actual rate of exchange to \$10,345 million

2023	\$10,345m
2022	\$9,808m
2021	\$5,963m

\$10.3bn

Reported operating profit

Up 118% at actual rate of exchange to \$8,193 million (up 134% at CER)

2023	\$8,193m
2022	\$3,757m
2021	\$1,056m

\$8.2bn

Core operating profit

Up 9% at actual rate of exchange to \$14,534 million (up 14% at CER)

2023	\$14,534m
2022	\$13,350m
2021	\$9,928m

\$14.5bn

Reported EPS

Up 81% at actual rate of exchange to \$3.84 (up 96% at CER)

2023	\$3.84
2022	\$2.12
2021	\$0.08

\$3.84

Core EPS

Up 9% at actual rate of exchange to \$7.26 (up 15% at CER)

2023	\$7.26
2022	\$6.66
2021	\$5.29

\$7.26

// Denotes a scale break. Throughout this Annual Report, all bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

□ For more information:

In relation to the inclusion of Reported performance, Core financial measures and constant exchange rate (CER) growth rates as used in this Annual Report, see the Financial Review from page 58.

For the reconciliation between Reported and Core performance, see the Reconciliation of Reported results to Core results in the Financial Review on page 62.

¹ As detailed from page 152, Total Revenue consists of Product Sales, Alliance Revenue and Collaboration Revenue.

Contents

Strategic Report

Chair's Statement 2
 Chief Executive Officer's Review 3
 AstraZeneca at a Glance 5
 What science can do: artificial intelligence 6
 Healthcare in a Changing World 7
 Our Purpose, Values and Business Model 10
 Our Strategy and Key Performance Indicators 12
 Therapy Area Review 16
 > Oncology 16
 > BioPharmaceuticals 20
 – Cardiovascular, Renal & Metabolism 22
 – Respiratory & Immunology 24
 – Vaccines & Immune Therapies 26
 > Rare Disease 28
 Business Review 32
 EU Taxonomy Disclosure 50
 Task Force on Climate-related Financial Disclosures Summary Statement 51
 Risk Overview 54
 Financial Review 58

Corporate Governance

Chair's Introduction 76
 Corporate Governance Overview 77
 Board of Directors 78
 Senior Executive Team (SET) 80
 Corporate Governance Report 81
 Nomination and Governance Committee Report 90
 Science Committee Report 92
 Sustainability Committee Report 93
 Audit Committee Report 94
 Directors' Remuneration Report 102
 Remuneration Policy 127

Financial Statements

Preparation of the Financial Statements and Directors' Responsibilities 140
 Directors' Annual Report on Internal Controls over Financial Reporting 140
 Auditors' Report 141
 Consolidated Statements 148
 Group Accounting Policies 152
 Notes to the Group Financial Statements 160
 Group Subsidiaries and Holdings 211
 Company Statements 216
 Company Accounting Policies 218
 Notes to the Company Financial Statements 220
 Group Financial Record 223

Additional Information

Shareholder information 225
 Directors' Report 227
 Sustainability supplementary information 230
 Trade Marks 231
 Glossary 232
 Cautionary statement regarding forward-looking statements 236